cbd54c6f-2634-4ac6-ba5a-73cb4680867a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59.7481177275838
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- TNFA_SIGNALING_VIA_NFKB+0.470
- INFLAMMATORY_RESPONSE+0.430
- COAGULATION+0.400
- HEDGEHOG_SIGNALING+0.380
- KRAS_SIGNALING_UP+0.360
- ALLOGRAFT_REJECTION+0.350
- COMPLEMENT+0.350
- TGF_BETA_SIGNALING+0.350
- IL6_JAK_STAT3_SIGNALING+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.570
- MYC_TARGETS_V1-0.560
- OXIDATIVE_PHOSPHORYLATION-0.490
- CHOLESTEROL_HOMEOSTASIS-0.420
- DNA_REPAIR-0.410
- MTORC1_SIGNALING-0.370
- MITOTIC_SPINDLE-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.935 |
| 2 | d552ba81-1140-4ab6-a14c-659c07e494d0 | — | — | 0.930 |
| 3 | 20020074.LumA | — | A | 0.925 |
| 4 | 1b192a49-01cb-4459-a7a7-fdebe428f386 | — | — | 0.922 |
| 5 | fdeb45e1-cce1-49ce-9f87-50c780d7f185 | — | — | 0.921 |
| 6 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.920 |
| 7 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.920 |
| 8 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.919 |
| 9 | SRR8518425 | — | A | 0.917 |
| 10 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |